Physician profile
Christopher Bruno
NPI 1932385408
$48,418.25
in general payments reported to CMS, 2019-2025
51 companies · $939 in 2025
The $939 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $11K · 2021: $15K · 2022: $6,570 · 2023: $1,923 · 2024: $2,048 · 2025: $939.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,910.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,910.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $23,936.96 | 2019-2025 | Farxiga |
| Dexcom, INC. | $10,689.32 | 2019-2024 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $5,934.41 | 2019-2023 | Steglatro, Segluromet, Steglujan |
| Novo Nordisk INC | $992.62 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $890.22 | 2019-2025 | Mounjaro, Jardiance, Baqsimi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $591.86 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $537.50 | 2021-2025 | |
| Medtronic, INC. | $537.08 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Sanofi-Aventis U.S. LLC | $514.33 | 2020-2025 | |
| Abbott Laboratories | $510.42 | 2019-2025 | Freestyle Libre 3 |
| Amgen INC. | $436.07 | 2019-2025 | Evenity, Prolia, Repatha |
| Ibsa Pharma INC. | $390.71 | 2022-2025 | Tirosint, Licart, Licart |
| Abbvie INC. | $255.00 | 2020-2025 | Synthroid |
| Tandem Diabetes Care, INC. | $187.43 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Alexion Pharmaceuticals, INC. | $145.51 | 2022-2025 | Strensiq |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Bruno listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.